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The role of vasoactive intestinal peptide (VIP) in the development of form deprivation myopia (FDM) 
was examined. Daily intravitreal injection of porcine VIP reduced, but did not eliminate FDM at a 
maximal daily dose of l x10  -5 mol/injection. A VIP analogue reported to be relatively 
hydrolysis-resistant in vivo, had no effect on development of FDM at any dose tested. Two VIP 
antagonists completely abolished FDM. The one reported to be selective for central nervous ystem VIP 
receptors was 100 times more potent than one reported to be selective for peripheral nervous system 
receptors (EDso=2 x 10 -1° and 2 x 10 -s tool/injection respectively). By immunofluorescence using 
antiserum to porcine VIP, VIP-like immunoreactivity was localized to a subset of amacrine cells (AC) 
and in three parallel layers in the inner plexiform layer (IPL) (10%, 40% and 70% of IPL thickness 
from the AC layer). Immunoreactive nerve fibres were also seen in the choroid, the ciliary body and the 
iris. These results suggest hat VIP may play a role in both normal development of the refractive 
properties of the eye, and in the development of FDM. 
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INTRODUCTION 
Although the effect of form deprivation on ocular growth 
has now been well characterized, the underlying retinal 
mechanism and the biochemical factors involved in 
development of form deprivation myopia (FDM) have 
yet to be elucidated. Several bioactive substances found 
in the retina have been implicated in the processes 
underlying FDM in the chick, including acetylcholine 
(Stone, Lin & Laties, 1991), dopamine (Stone, Lin, Laties 
& Iuvone, 1989; Rohrer, Spira & Stell, 1993a) and basic 
fibroblast growth factor (bFGF) (Rohrer, Negishi, Tao & 
Stell, 1993b). The role of these retinal substances in 
FDM has been investigated by studying the effect of 
various agonists and antagonists on the development of
FDM. 
One retinal peptide that may be involved in ocular 
growth is vasoactive intestinal peptide (VIP), a highly 
basic, single-chain peptide containing 28 amino acids, 
which was originally isolated from porcine gut (Said & 
Mutt, 1972). VIP has since been found to be distributed 
extensively throughout both the central and peripheral 
nervous ystems in most species (Said, 1984). In the chick 
retina, VIP has been localized to a subset of amacrine cells 
(representing about 1% of the total amacrine cell 
population) (Fukada, Kuwayama, Shiosoka, Inagaki, 
Ishimoto, Shimizu, Takagi, Sakanaka, Takatsuki, Senba 
& Tohyama, 1981). It has been shown immunocytochemi- 
cally, that retinal VIP levels may be increased in FDM in 
monkeys (Raviola, Wiesel, Reichlin, Lam & Chetri, 
1991). It has also been found that VIP stimulates apical 
secretion of proteins of various molecular weights from 
cultured chicken retinal pigment epithelium (Koh et al., 
1991). Both these findings suggest hat VIP warrants 
investigation as a potential regulator or modulator of eye 
growth. 
The purpose of the current studies was three-fold: 
(1) 
(2) 
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to characterize pharmacologically the effect of 
exogenous VIP agonists and antagonists on the 
development of FDM in the chick; 
to localize endogenous VIP in the various tissues 
of the eye, and to determine whether FDM has an 
effect on the apparent amount of VIP in these tissues; 
and 
to identify the origin of VIP-immunoreactive fibers in 
the eye through immunocytochemical examination of 
the ciliary ganglion. 
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MATERIALS  AND METHODS 
Animals 
Male leghorns (Gallus domesticus) were obtained on the 
day of hatching (Lillydale Hatchery, Linden, Alta). 
Chicks were housed under fluorescent light on a cycle of 
12 hr light, 12 hr dark with light onset at 07:00. Chicks 
were held for the first week in a large stainless teel 
brooder, at a room temperature of approx. 25°C. There- 
after chicks were kept in clear Nalgene ~cages. Chicks 
were fed water and Purina ~ chick starter ad libitum. 
Induction of myopia 
Translucent goggles formed from a plastic laminate 
were attached with cyanoacrylic glue to the skin 
surrounding the right eye of each chick. Goggles were 
22 mm in diameter and 7 mm deep, with a small notch at 
the top to allow for ocular injections without goggle 
removal. The left eye was left occluded to serve as a 
control. Chicks were occluded immediately after injection 
of the first dose of drug. 
In vivo injections 
Injections were performed under anaesthesia (1.5% 
halothane, 50% N20, 50% 02). The animals received 
daily injections for a period of 8 days into the vitreous 
chamber of the eye, using a Hamilton syringe with 26 
guage needle. Injections were made at 13:00 hr each day, 
approximately half-way through the light cycle. The 
injections were carried out between day 10 and day 17. 
The test substance was injected in 20 #1 of sterile saline. 
The unoccluded eyes were injected with 20 pl of saline. 
Assessment of myopia 
At the end of the treatment period, all eyes were 
assessed for refractive rror using a streak retinoscope 
and trial lenses. Refractive rror was assessed to the 
nearest 0.5 D. A working distance of 0.5 m was used in all 
cases. Ocular dimensions of the chicks were measured 
either by using A-scan ultrasonography (Ophthascan 
"S", Biophysics Medical Inc.) without cycloplegia, or by 
whole eye measurement with callipers after enucleation. 
Elimination of myopia was judged to occur when 
refractive rror was eliminated. 
Immunoc y tochemis try 
Enucleated chick eyes were bisected along the equator 
and fixed in Zamboni's fixative overnight at 4°C 
(Zamboni & DeMartino, 1967). The eye halves were then 
infiltrated with 30% sucrose. Pieces of either the anterior 
half (including lens, iris and ciliary body) or the posterior 
half (including sclera, choroid, retinal pigment epithelium 
and retina) were embedded in OCT compound, frozen, 
cut in cross-section atapprox. 5-7 pm and mounted on 
gelatin coated slides. 
Slides were washed three times for 10 min each in 
0.05 M phosphate buffered saline (PBS), then incubated 
for 30 min with 5% normal goat serum. The primary 
antibody, a rabbit polyclonal anti-VIP (Epstein) was used 
at various dilutions. PBS diluent (0.05M PBS 
pH 7.4_0.3% Triton X-100+0.1% sodium azide) was 
used in all cases. The slides with primary antibodies were 
incubated overnight at room temperature. After a further 
wash in PBS (3 × 10 min), the VIP-like immunoreactivity 
(IR) was localized by indirect immunofluorescence using 
a FITC-labelled goat anti-rabbit secondary antibody 
(Jackson ImmunoResearch Inc., West Grove, Pa). 
A possible source of IR fibres in the retina was 
investigated through staining of the ciliary ganglion. 
Animals (n=-4) were injected with colchicine [10/~1 of 
0.25% (w/v)] into the retrobulbar space. The chicks were 
sacrificed after 24 hr and the ciliary ganglion removed and 
fixed for frozen sectioning as described above. Frozen 
sections (5-7 pm) were mounted on gelatin-coated slides. 
VIP-like IR was localized as described above. 
Specificity of the primary antibody was tested both by 
comparing results using a second primary antibody (a 
commercial rabbit polyclonal antiserum from Amer- 
sham, Arlington Hts, Ilk) and by preabsorption of the 
primary antibody with porcine VIP (Sigma Chemical 
Company, St Louis, Mo.). 
RESULTS 
Effect of VIP agonists and antagonists on the development 
of FDM 
The effects of intravitreal injection of several VIP 
agonists and antagonists on development of FDM were 




















F IGURE 1. Effect of VIP agonists and antagonists on development of
FDM. Drug dose represented is the lowest dose giving the maximum 
effect for each drug. The drug was administered daily in 20 pl of saline. 
VIP--porcine VIP (Sigma) 1 × 10 ~ mol/injection; CNS antagonist- -  
central nervous system antagonist (Gozes) I x  10 5mol/injection; 
PNS antagonist--peripheral nervous system antagonist (Pandol) 
1 × 10 5mol/injection; Hoffman LaRoche agonist 1 × 10 ~0 mol/ 
injection. Error bars represents SD (n = 6 per group). 
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F IGURE 2. Dose-response curve (refractive rror) for development of
FDM with daily injection of porcine VIP. Dose represents daily 
intravitreal dose (mol/injection) administered in 20 #1 of saline. Error 
bars represents SD (n = 6 per group). 
error between the test (OD) and control (OS) eyes for the 
lowest daily dose giving the maximum effect for each of 
the agonists and antagonists ested. 
Chicks that received aily injections of saline into both 
the goggled and the control eyes developed significant 
myopia in the goggled eye within the 8 day test period. 
These chicks (n = 6) showed a mean refractive rror of 
-6D while the control (ungoggled) eyes were 
emmetropic (0D of refractive rror). There was a mean 
difference of 0.6 mm in axial length between the goggled 
eye and the control. The difference in both the axial 
lengths and the refractive rrors between the goggled and 
the control eye is statistically significant at the 5% level 
(Student's t-test). 
Daily injection of VIP (porcine, Sigma Chemical 
Company, St Louis, Mo.) led to a decrease in 
development ofFDM in a dose-dependent manner, with 
an EDs0 of approx. 2 x 10 -s mol/daily injection (Fig. 2). 
The maximal dose produced a decrease inrefractive rror 
in the goggled eye from -6  to -2  D, and a decrease in 
difference inmean axial ength from 0.6 to 0.25 mm. This 
represents a maximum decrease in degree of myopia of 
approx. 66% (based on refractive rror) at a daily dose of 
l x  10 -5 #g in 20#1 of saline, or 6nM maximum 
concentration to the retina, assuming dilution in a liquid 
vitreous volume of 150 #1. 
VIP has been found to be extremely abile in vivo. Some 
VIP fragments formed by hydrolysis in vivo (e.g. VIP 
10-28) have been found to act as VIP antagonists 
(Westendorf, Phillips & Schonbrunn, 1983). Therefore a
less labile VIP analogue (Hoffman LaRoche, Nutley, N.J. 
Peptide RO 246795), expected to yield lesser amounts of 
antagonistic peptide fragments, was tested. Use of this 
drug at the EDs0 (2 x 10 -8 mol/injection) found for VIP 
led to pathological changes in the injected eye, including 
clouding of both the aqueous and the vitreous humours. 
Daily injections of this peptide at lower doses (1 × 10-~0 
1 x 10-", 1 x 10 -12 mol) had no effect on the development 
of FDM. The mean difference in eye size, at the highest 
daily dose tested, was 0.6 mm, the same as the control 
group. When injected into ungoggled eyes at the doses 
used above, this peptide did not induce any change in eye 
size or refractive rror. It appeared that a pure VIP 
agonist had no effect on growth of either normal or 
form-deprived eyes at the doses given. 
These results uggested that the FDM-limiting effect of 
VIP might be due to the presence of peptide antagonists 
fragments generated by hydrolysis of injected VIP in vivo. 
To test this hypothesis, two V1P antagonists were used. 
The first, a hybrid peptide consisting of the C-terminal of 
the VIP molecule linked serially to the N-terminal portion 
of neurotensin, was designed to study VIP effects in the 
central nervous system (Gozes, McCune, Jacobson, 
Warren, Moody, Fridkin & Brenneman, 199l). The 
second, a modified VIP molecule ([4CI-D-PhC, Leu 17] 
porcine VIP), was designed and characterized for action 
in the peripheral nervous system (Pandol, Dharm- 
sathaphorn, Schoffield, Vale & River, 1986). 
Both antagonists reduced evelopment of FDM in a 
dose-dependent manner (Fig. 3). However, there was a 
two orders of magnitude increase in the EDs0 for the 
"peripheral" antagonist compared to the "central" 
antagonist (2× 10-1°mol/daily injection for the CNS 
antagonist vs 2 × 10 -8 mol/daily injection for the PNS 
antagonist). 
To summarize, daily injections of VIP reduced but did 
not eliminate FDM. A more stable VIP agonist had no 
effect of development ofFDM. Two VIP antagonists both 
eliminated the myopia, but with different efficacies. None 
of these agents had any effect on growth of unoccluded 
eyes. 
Immunoc y t ochemis try 
In control eyes, VIP-like immunoreactivity was 
localized in the retina to cell bodies in the amacrine cell 
layer, and in three parallel fibre layers at 10%, 40% and 
70% depth in the inner plexiform layer (IPL) measured 
from the amacrine cells [Fig. 4(a)]. VIP immunoreactive 
fibres were also observed in the choroid, the ciliary body 
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F IGURE 3. Dose-response curves (refractive rror) for development of
FDM with daily injection the central nervous ystem (Gozes) and the 
peripheral system (Pandol) antagonists ( ee text). Dose represents daily 
intravitreal dose (mol/injection) administered in 20 pl of sterile saline. 
Error bars represent SD (n = 6 per group). 
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FIGURE 4. Vasoactive intestinal peptide immunoreactivity in (a) retina; (b) choroid and (c) iris and ciliary body. 
Immunofluorescent localization with FITC labelled secondary antibody. (a) Antibody labels amacrine cells (arrows) and three 
fibre layers in the IPL (1, 2 and 3). (b) Antibody labels fibres in the choroid (arrow). s, sclera; rpe, retinal pigment epithelium. 
(c) Antibody labels fibres in the iris musculature (a) and in the ciliary body (arrow) and in the surrounding the iris vasculature 
(c). L, lens; CB, cililary body; IM, iris muscle. 
and iris masculature [Fig. 4(b,c)]. Preabsorpt ion of the 
diluted ant ibody with porcine VIP (Sigma) 1 x 10 _5 to 
1 × 10 8M) overnight, prior to pr imary incubation, 
prevented all staining. 
A subjective compar ison of the brightness of  staining 
was carried out at five different ant ibody dilutions (1:200, 
1:400, 1:800, 1:1600 and 1:3200) in order to assess the 
relative amount  of  VIP like immunoreact ivity in the 
myopic and control eyes. These assessments revealed no 
difference in staining intensity between the myopic and 
the control  eyes, in either the retina, the IPL, the choroid 
or the iris and ciliary body. 
Certain transmitters and peptides, including met- 
enkephalin and dopamine, are synthesized and released 
from amacrine cells by light- and dark-dependent 
mechanisms (Iuvone, Galli, Garr ison-Gund & Neff, 1978; 
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Luo, Stell & Cupo, 1991). In order to examine the effects 
of light and dark on storage and release of VIP, dark- and 
light-adapted myopic and control eyes were fixed and 
stained with the VIP antiserum at the same antiserum 
concentrations as above. There was no evidence of 
variation in the intensity of staining in any of the tissues 
examined. 
Within the ciliary ganglion and nerves immunoreactive 
VIP staining was localized to a few fibres. There was no 
evidence of VIP-IR cell bodies anywhere within the ciliary 
ganglion, suggesting that the ciliary ganglion is not the 
origin of the VIP-IR fibres within the retina (Fig. 5). 
DISCUSSION 
Development of the refractive properties of the eye in 
the post hatching chick is dependent on a clear retinal 
image. Disturbance of this image by application of a 
goggle over one eye leads to increased growth of the eye 
and significant myopia. The nature of the biochemical 
signals involved in both normal growth and in FDM 
remains unclear. 
FDM was partially blocked by daily injections of VIP. 
When a pure VIP agonist was tested in the same system. 
FIGURE 5. Vasoactive intestinal peptide immunoreactivity in the 
ciliary ganglion and ciliary nerve, pretreated with colchicine (see text). 
The antibody stains occasional fibres in the ganglia (a) and the nerve 
fibres emerging from it (b). 
FDM was not blocked at any of the three doses tested. 
When injected into the ungoggled eye this drug had no 
apparent effect on ocular development. These findings 
suggest that increasing amounts of exogenous VIP do not 
directly control ocular growth. However they do not rule 
out the involvement of endogenous VIP in the 
development of FDM. 
The results of screening studies using VIP antagonists 
support a role for endogenous VIP in the development of
FDM. Both of the antagonists tested blocked develop- 
ment of FDM almost completely, although with different 
efficacies. The blocking effect of both the VIP antagonists 
is evidence that endogenous VIP plays a role in the 
development of form deprivation myopia, and that the 
effect of endogenous VIP can be blocked by a pure 
antagonist. 
The partial rescue effect of porcine VIP observed here 
may in fact be due to the antagonist effect of VIP 
fragments. This assumption seems possible, since both 
antagonists blocked development of FDM, and the VIP 
analogue known to be less labile in vivo had no apparent 
effect on development of FDM. 
The VIP CNS antagonist (Gozes et al., 1991) was 
designed to investigate the interaction of VIP with its 
receptors in the CNS. It has been characterized previously 
only in the mammalian ervous ystem. This antagonist 
was found to inhibit VIP binding and attenuate 
VIP-stimulated cAMP accumulation in cell cultures 
derived from mammalian CNS. However, the antagonist 
is not specific for CNS receptors, having been shown to 
have some peripheral effects (Gozes et al., 1991). The 
peripheral antagonist (Pandol et al., 1986) has been 
shown to antagonize the action of peptides that interact 
with the VIP receptor in the exocrine pancreas of the rat. 
This antagonist to date has not been shown to have an 
effect in the CNS, although an effect cannot be ruled out. 
There are at least two possible explanations for the 
result observed. First the two antagonists may be exerting 
their effect at two different sites, one central and one 
peripheral. Second both antagonists may act at the same 
site, but with different affinities. The ocular binding site 
of the two antagonists i  currently being investigated. 
V|P has a widespread istribution in both the central 
and the peripheral nervous ystems. In the eye, our results 
confirm localization in both central (the retina) and 
peripheral (choroid, iris and ciliary body) neural 
components of the chick eye. Because of this localization 
it may be possible to study the influence of both the CNS 
and the PNS on ocular growth and development. 
In this study, VIP has been localized in both retina, 
which is embryologically and anatomically part of the 
central nervous system, and in peripheral neural 
components of the eye (choroid, iris and ciliary body) in 
the chick eye. In the retina VIP was found in a subset of 
amacrine cells in the retina, and in three layers in the IPL. 
VIP-IR fibres were also found in the choroid, usually 
associated with blood vessels. Since VIP is a potent 
vasodilator, its presence in the vascular choroid is not 
surprising. Shih, Fitzgerald, Norton, Gamlin, Hodas and 
Reiner (1993) have demonstrated a reduced choroidal 
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blood flow in chicks wearing goggles that induce 
myopia. Modulation in release of VIP from nerve 
fibres in the choroid may have an effect on choroidal 
blood flow. We found no apparent change in the 
intensity of staining of the choroidal fibres in this 
study. However, this method may not be sufficiently 
sensitive to detect changes in storage and release which 
may in fact be occurring. For example, if a large 
reservoir of unprocessed precursor is immunoreactive, 
changes in release of processed peptide may be 
undetectable. 
The localization of VIP to the choroid, retina, 
iris and ciliary body does suggest that VIP may 
have independent effects on several regions of the 
eye. It may be possible to study the several roles 
of these systems on ocular growth and develop- 
ment. 
Our results suggest hat the choroidal VIP immune- 
reactive fibres do not originate from ciliary ganglion 
cells; the source of these fibres remains to be identified. 
These findings are surprising, since it has been 
suggested (at least in the pigeon) that control of 
blood flow within the choroid is controlled visually 
by parasympathetic pathways from the nucleus of 
Edinger-Westphal via projections to the ciliary 
ganglion (Reiner, Karten, Gamlin & Erichsen, 1983). 
We are currently examining the superior cervical 
ganglion of the chick as one alternate source Of 
VIP-IR fibres in the eye. The role of VIP in regula- 
tion of choroidal blood flow warrants further investi- 
gation. 
No difference was found between the intensity of 
staining in the myopic eye as compared to the control 
eye, at any concentration of antibody used. As noted, 
these methods could not rule out the possibility that 
FDM might alter the rate of release of VIP. As 
previously stated the method used in this study may 
not be sensitive enough to detect small changes in 
either VIP synthesis or release, especially if a large 
reserve of VIP precursor is immunoreactive. In rabbits, 
there is some evidence that receptor sensitivity to VIP 
may change with the circadian cycle (Kiuchi, Hirota & 
Gregory, 1993). If FDM had an effect on receptor 
sensitivity, this may not be reflected in changes in VIP 
production and release. 
Several synaptic transmitters and neuropeptides 
normally localized in the retina have been shown to 
be affected by, and to have an effect on, the 
development of FDM. For example, daytime dopa- 
mine levels in the chick are found to drop by about 
30% (Stone et al., 1989) in FDM. Apomorphine, a 
nonspecific dopamine agonist prevents FDM in a 
dose-dependent manner (Rohrer et al., 1993a, b). 
However, no peptide has been shown previously to 
have definitive control of ocular growth and develop- 
ment. The mechanism of action of these and other 
neuropeptides remains unclear. It seems likely that 
ocular growth occurs as a result of interaction between 
a number of neural subsystems using a variety of 
intercellular messengers. 
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